BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Scientific Program
 
BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Theme: Rethinking the Next Big Things in Pharma Innovations
Time: August 16-19, 2018 
Place: Boston Marriott Cambridge, USA
 
Scientific Program
Stream 1 Stream 2 Stream 3 Stream 4 Stream 5

 

Stream 3: Industrial Art Gallery
-Arts in Billion Dollar Molecules and Next Generation Therapy

Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets
Substream 3-2: Novel Small Molecule Inhibitors and Agonists
Substream 3-3: Follow-on Drugs and Repositioning Drug Discovery
Substream 3-4: Novel Biotherapeutic Discovery
Substream 3-5: Smart DDS and Nanomedicine

Substream 3-6: Clinical Trial Gateway and Translational Convergence

Substream 3-7: Arts of Next Generation Therapy

 

Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets
 

Session 3101: Improved Targeted Drug Discovery

Day 1: Afternoon, Thursday, August 16, 2018

Place: Endeavor Room, 3rd Floor

15:25-17:10

Chair: Dr. Scott Hansen, Associate Professor, The Scripps Research Institute, USA
Time FaceOn Speeches and Speakers
15:25-15:30 Chair's Introduction
15:30-15:50
 

Title: Using Ligand Bias to Refine Novel Dopamine D1 Receptor Agonists

Dr. John A. Allen, Assistant Professor, Pharmacology and Toxicology, University of Texas Medical Branch; Principal Scientist, Neuroscience Research Unit, Pfizer, Inc., USA

15:50-16:10

Title: Targeting the PIP2 Paradigm of Lipid-gated Ion Channels in HTS Drug Discovery

Dr. Scott Hansen, Associate Professor, The Scripps Research Institute, USA

16:10-16:30

Title: New Target to Treat Neurodegenerative Disorders: RNA Binding Protein – mRNA Complex

Dr. Maria Maccecchini, Founder & CEO, QR Pharma, Inc., USA

16:30-16:50

Title: Glucagon-like Peptide 2 Prevents Down-regulation of Intestinal Multidrug Resistance-associated Protein 2 Induced by Experimental Endotoxemia

Dr. Maite R. Arana, Post-doctoral Fellow, Institute of Experimental Physiology, Argentin
a
16:50-17:10 \

Title: Drug Resistance, An Enemy of Targeted Cancer Therapies

Dr. Alan M. Kleinman, Physician, Merced Faculty Associates, USA

 

Session 3102: Biomarkers, Personalized Medicine and Pharmacogenomics

Day 2: Afternoon, Friday, August 17, 2018

Place: Enterprise Room, 3rd Floor

13:30-15:15

Chair: Dr. Shanrong Zhao, Director, Pfizer Worldwide Research and Development, USA
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55 Title: Identify Genes Implicated in Kidney Disease Pathogenesis by Comprehensive RNA-seq Data Analysis

Dr. Shanrong Zhao, Director, Pfizer Worldwide Research and Development, USA

13:55-14:15 Title: Multi-omics Based Data Driven Protocols for Biomarker Discovery and Complementary Diagnostic Development
Dr. Vladimir Tolstikov, Director, BERG LLC,USA
14:15-14:35

Title: Identification of a Predictive Gene Signature through Machine Learning for Therapeutic Response – A Case Study of Clinical Genomic Data

Dr. Hyunjin Shin, Senoir Scientist, Data Science Institute, Takeda Pharmaceuticals, USA

 

14:35-14:55 Title: The Biochemistry of Human Flavin-containing Monooxygenase 3 (FMO3) and Its Strict Connection to the TMAO Biomarker
Dr. Gianluca Catucci, Assistant Professor, Department of Life Sciences and Systems Biology, University of Turin, Italy
14:55-15:15

Title: Development of Animal Models to Screen the Metabolic Biomarkers in Multiple Sclerosis.

Dr. Kouichi Ito, Associate Professor, Rutgers-Robert Wood Johnson Medical School, USA

 

15:15-15:30 Coffee Break

     

© 2003-2018 All rights reserved by BIT Congress Inc.
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897